Acasti Pharma (GRCE) EBITDA (2019 - 2026)
Acasti Pharma (GRCE) EBITDA from Jun 30, 2019 to Mar 31, 2026. The TTM Acasti Pharma (GRCE) EBITDA is -$11M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Acasti Pharma (GRCE) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -33.59% |
| 3 Years TTM | -40.30% |
| 5 Years TTM | -7.41% |
| All Time TTM | -9.89% |
Annual EBITDA change of Acasti Pharma (GRCE)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$11M | -33.59% |
| 2025 | -$17M | +29.83% |
| 2024 | -$13M | -75.32% |
| 2023 | -$52M | +233.74% |
| 2022 | -$16M | -4.24% |
| 2021 | -$16M | -32.25% |
| 2020 | -$24M | -29.37% |
| 2019 | -$34M | +72.69% |
| 2018 | -$20M | +2636.11% |
| 2017 | -$720K | -88.59% |
| 2016 | -$6.31M | N/A |
Comparison Acasti Pharma (GRCE) five years EBITDA CAGR with competitors
Acasti Pharma (GRCE) five years EBITDA CAGR is -7.42%.